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Introduction
Data compiled over the past decade for patients on the
heart, lung, and heart/lung waiting lists and for those
receiving these thoracic organs were analyzed to assess
the importance of patient demographics, risk factors, and
primary cardiopulmonary disease on trends in waiting list
time and mortality. Analysis also sought to identify the
characteristics of thoracic transplant recipients and their
associated post-transplant outcomes. Unless otherwise
noted, the statistics in this article come from reference
tables in the 2002 OPTN/SRTR Annual Report. Two com-
panion articles in this report, ‘Data Sources and Structure’
and ‘Analytical Approaches for Transplant Research’,
explain the methods of the data collection, organization,
and analysis that serve as a basis for this article (1,2).
It is intended that this analysis and review will highlight
the evolution of thoracic transplantation in the United
States over the past decade and provide insights that
may lead to more efficacious allocation of donor organs
and improved outcomes. By reviewing data such as these,
transplant practices may be identified and prospective
studies planned that will form the scientific basis on
which to advance thoracic organ allocation policy and the
field of thoracic organ transplantation.
Heart
Heart waiting list characteristics
The number of registrants on the heart transplant waiting
list steadily increased from 2655 in 1992 to 4149 in 1998.
This represents the high-water mark for the heart trans-
plant waiting list. Unlike all other organs, the size of the
heart waiting list has been fairly stable since 1998, and
there were 4096 registrants at the end of 2001. In 2001,
53% of registrants were aged 50–64 years, 21% were
aged 35–49 years, and 12% were aged 65 and older
(Figure 1). The greatest change over the past decade
was among those over 65 years, who represented 4% of
the heart waiting list population in 1992 and 12% in 2001,
a 300% increase in proportion. Also of note is the decline
of 8% over the decade in the proportion of registrants
aged 35–49 years (despite relatively stable absolute num-
bers on the waiting list), a trend that reflects a more
aggressive and inclusive approach to patients over
65 years. The number of patients in the latter group has
increased more than fourfold during the past decade.
Among wait-listed registrants, 84–86% of registrants
were white, 12–14% African American, and 0.6–1.4%
Asian, with smaller percentages classified as other/multi-
race or unknown. As for ethnicity, 7% were Hispanic/
Latino in 2001. Women represented only 17% of the wait-
ing list population in 1992 and 22% in 2001.
Although the media occasionally emphasize that resident
aliens are listed, over the past 9 years, US residents
constituted from 98.9–99.5% of all registrants on the
heart waiting list, with only 0.1–0.5% of non-US residents
listed.
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From 1992 to 2001, registrants at year-end had dramat-
ically different profiles with regard to their accrued time on
the waiting list (Figure 2). The percentage of registrants
waiting 1 year or less at each year-end decreased almost
50%. The percentage of registrants waiting 1–2 years was
relatively consistent, and those waiting more than 2 years
quadrupled from 11% of the waiting list population to
46%. Part of the latter increase may be related to a doub-
ling of the percentage of those designated with a tempor-
arily inactive status, from 23% to 45%. From 1992 to 1998,
the percentage of Status 1 patients increased from 6% to
10%, at which point Status 1 patients were subcategorized
into 1A and 1B. For the remainder of the decade, Status 1A
patients made up 2–3% of those on the waiting list and
Status 1B patients 8–11%.
Over the last 3 years, Status 1A patients have made up
about 20% of the Status 1 category. This fairly high degree
of stratification indicates success in separating out the
small percentage of patients at highest risk. The percent-
age of Status 2 patients markedly decreased over the past
decade, dropping from 71% to 45%, with a concomitant
increase in the percentage who were temporarily inactive,
possibly because of improved outcomes with medical
therapy.
In 1992, there were 3965 new registrations on the heart
transplant waiting list. This peaked at 4247 registrants in
1995 and was lowest in 2001 at 3402. Median time to
transplant decreased from 406 days in 1992 to 266 days in
2001 (Figure 3).
A considerable amount of fluctuation occurred from year
to year in median time to transplant among children. The
number of registrants over 65 increased from 140 in 1992
to 246 in 2001. Interestingly, their median time to trans-
plant was well under a year.
When examining race and ethnicity, the median time to
transplant for whites varied from 398 days in 1992 to
268 days in 2001. African Americans had higher median
times to transplant, the highest being 654 days in 1993,
but this decreased to between 283 and 329 days over the
past 4 years. Asians had a median time to transplant of
6 months or less, but with a small number of Asian regis-
trants listed, confidence intervals for these medians were
very wide. Median time to transplant for the other/multi-
race group was quite variable and was 264 days in 2001.
For the most part, the Hispanic/Latino registrants had a
median time to transplant of 6 months to 1 year.
The median time to transplant for women was consistently
shorter than that for men, varying from 174 days in 2001 to
265 days in 1995. For men during that same time, the
median time to transplant ranged from 310 days to
319 days.
Patients with type O blood consistently had the longest
median time to transplant, generally 2–3 years (Figure 4).
Those with type A or type B averaged less than 1 year, and
those with type AB averaged 2–4 months. When median
time to transplant for patients having their first transplant
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Figure 1: Age distribution of heart waiting list registrants at
year-end, 1992–2001. Source: 2002 OPTN/SRTR Annual Report,
Table 11.1.
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Figure 2: Accrued waiting time for heart waiting list registrants at
year-end, 1992–2001. Source: 2002 OPTN/SRTR Annual Report,
Table 11.1.
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Figure 3: Median time to heart transplant, by year, 1992–2001.
Source: 2002 OPTN/SRTR Annual Report, Table 11.2.
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is compared with those who had a prior transplant of any
organ, waiting time was considerably longer for the
re-transplant patients.
The effect of initial listing status was examined, and it was
found that the historic Status 1 patients from 1992 to 1999
had a median time to transplant varying from 70 days to
153 days, with the time in 1999 being 139 days. At that
point, Status 1 was split into Status 1A and 1B. The
median time to transplant for patients initially listed as
Status 1A in 1999–2001 varied from 99 days to 144 days, the
lowest being in 2000. Patients initially listed as Status 1B
had a slightly shorter median time to transplant (93 days
in 2001 and 112 days in 2000), though the confidence
limits for Status 1A and Status 1B median time to
transplant overlapped substantially during this time per-
iod. Status 2 patients averaged 18 months to 2 years for
their median time to transplant.
Waiting list annual death rates per 1000 patient years at
risk decreased over the past 10 years. In 1992, the death
rate was 317, a figure that decreased to 151 in 2001. The
highest death rate by age group was among infants, and
this also decreased from 2591 to 1373 over the past
10 years. During 2001, patients aged 1–5 years had a
death rate of 377. Paradoxically, the oldest registrants
had the lowest waiting list death rate. Selectivity in the
acceptance of patients and the willingness of some pro-
grams to accept higher risk donors for this older age
patient recipient group may account for the latter finding.
The annual death rate per 1000 years at risk for the total
waiting list population in 2001 was 151 (whites, 148;
African Americans, 164; Asians, 148; and other/multirace,
233). For those of Hispanic/Latino ethnicity, the annual
death rate in 2001 was 158 per 1000 patient years
compared with 151 for all patients and 158 for the non-
Hispanic/non-Latino group. When analyzing the data for
gender differences, the annual death rate per 1000 patient
years at risk for women varied from 168 in 1999 to 376 in
1992. For men it varied from 143 in 2000 to 306 in 1992.
The annual death rate for those on the waiting list with
blood type AB ranged from a low of 153 in 2000 to a high
of 419 in 1992. Type O patients, who are of some concern
to the transplant community because of longer waiting
times, actually have a death rate very similar to the group
as a whole and to patients with blood types A and B.
As expected, the highest death rates by status at listing
are in the Status 1 and 1A groups. Status 1 patients from
1992 to 1998 had annual death rates of 549–867 per
1000 years, with 1 outlying year of 1190. After the Sta-
tus 1A and 1B categories were established, the death rate
for Status 1A was 976 in 2001, with a high of 1460 in
1999. Status 1B was somewhat less risky, having about
30% the risk as a Status 1A and ranging from 347 to 565,
the latter observed during the transition phase in 1999;
Status 2 had about one-tenth the risk of a Status 1A. Over
the past 5 years, Status 2 patients had death rates ranging
from 91 in 2001 to a high of 156 in 1997. These observa-
tions suggest that the existing medical urgency stratifica-
tion system is identifying the populations of transplant
patients at highest risk but that, conversely, these patients
are not being transplanted in a timely fashion.
Kauffman et al. (3) analyzed the determinants of waiting
time for heart transplants in the United States and also
found that blood type O correlates with the longest wait-
ing time and type AB with the shortest. They also found
that Asians had a particularly short waiting time. His-
panics/Latinos were somewhat between Asians and the
white and African American populations. In addition, their data
revealed that registrants over age 18 had a waiting time of
230days vs. 47–82days for the population under 18years.
Large regional variation was also noted regarding registrations
per million, waiting time, and transplants per million.
Chen and his colleagues (4) reported a multivariate ana-
lysis of factors affecting waiting time to heart transplant-
ation and found that priority status, blood type, and body
weight were the variables that most strongly affected
overall waiting time. Lower weight and blood type AB
were strongly associated with shorter waiting time.
Another confounding variable is the individual variation in
practice regarding the threshold for listing a patient.
Kauffman and his colleagues (3) mention that in regions
where more competition exists for organs, registrants
may get listed earlier and accrue longer waiting times.
This reflects the physicians’ interest in having their
patients accrue time in order to rise on the waiting list
and so get transplanted in a timely fashion to survive.
These variations in practice patterns and clinical pathways
are difficult to analyze.
Morrow et al. (5) examined listing-related outcomes for
heart transplantation in infants younger than 6 months.
They found that the interval to transplant increased as
age decreased, increased in patients without hypoplastic
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Figure 4: Median time to heart transplant by ABO blood type, 2000.
Source: 2002 OPTN/SRTR Annual Report, Table 11.2.
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left heart syndrome, and was correlated with smaller size
and blood group O in patients with hypoplastic left heart
syndrome. These authors felt that the distribution of type
O donor hearts to nontype O recipients accounted for the
higher mortality rate associated with blood type O.
In an attempt to develop a method for risk stratifying
Status 2 patients, Haywood and his colleagues (6)
analyzed the clinical characteristics of patients who died
on the Stanford heart transplant waiting list. To do this,
they analyzed registrants listed from 1986 to 1994 and
found that only low peak oxygen consumption and low
cardiac output predicted death on the waiting list. Unfor-
tunately, these predictors are not sufficiently available in
the data set reviewed. Morley (7) also used hemodynamic
profiling to predict death on the waiting list and found
associations for elevated right atrial pressure and a poor
hemodynamic risk score.
Lavee (8) compared death on the waiting list for patients
with ischemic cardiomyopathy vs. those with idiopathic
dilated cardiomyopathy and found that the actuarial
1-year survival was 61% in the ischemic group and 78%
in the idiopathic dilated cardiomyopathy group.
Heart transplant recipient characteristics
Over the last decade, the total number of heart transplants
remained relatively stable with 2170 transplants per-
formed in 1992 and 2202 such operations performed in
2001. Patients in their fourth, fifth, and sixth decades of
life accounted for the majority of transplant recipients; this
has remained unchanged since 1992. However, the per-
centage of recipients older than 65 gradually increased
from 4% in 1992 to 10% in 2001. From 1995 to 2001,
the percentage of heart transplants among Hispanic/
Latino patients increased from 5% to 9%, possibly reflect-
ing an increase in the Hispanic/Latino US population.
Recipient gender and racial breakdowns remained
unchanged.
The percentage of recipients who were not hospitalized
prior to transplantation ranged from a low of 27% in 1998
to 43% in both 1992 and 2000. Among all patients, the
percentage of those residing in the intensive care unit
(ICU) dropped from 59% in 1997 to 33% in 2001. Con-
versely, the percentage of recipients hospitalized outside
the ICU increased from 9% in 1997 to 22% in 2001. This
shift appears directly related to the change of Status 1 to
Status 1A and 1B in 1999. From 1999 through 2001, the
distribution of patient status assignments at time of trans-
plant remained stable; in 2001, 38% of patients were
classified Status 1A, 36% Status 1B, and 25% Status 2.
The majority of recipients had a primary diagnosis of either
coronary artery disease or cardiomyopathy in equal propor-
tions for the past 10 years. Congenital heart disease was
the third most common diagnosis (8% in both 1992 and
2001). Retransplantation accounted for 2–4% of trans-
plants over the decade of study.
Overall graft survival was 84% at 1 year (1999–2000
cohort) and 68% at 5 years (1995–1996 cohort). Given
the very low incidence of retransplantation, patient sur-
vival was only slightly higher than graft survival. At 1 year,
85% of recipients were alive and 70% were alive at
5 years, for the corresponding cohorts (Figure 5). While
infants less than 1 year of age had the lowest 3-month
graft survival at 86%, this same group had the best
5-year graft survival of 72%. The worst 5-year graft survival,
61%, was seen among those aged 1–5 years. By race,
5-year graft survival was lowest in African Americans at
54%, whereas whites and Asians had much higher 5-year
survival rates at 70% and 73%, respectively. Ethnicity,
gender, and blood type did not have a notable impact on
short- or long-term graft survival. Of all demographics, a
history of prior heart transplant portended the worst 5-year
graft survival, 49% vs. 69% in first-time heart transplant
recipients.
Patients not hospitalized immediately prior to transplant
had higher graft survival rates at 3 months and 1 year
compared with those hospitalized or residing in the ICU.
At 3 years, the difference between hospitalized and not
hospitalized was reduced. At 5 years, all these differences
were minimal. Similar patterns were seen in those
patients not on life support at the time of transplant com-
pared with those who were. Graft survival in relationship
to the primary diagnosis leading to transplant was highest
at 1 year for cardiomyopathy (87%) and coronary artery
disease (84%). The diagnoses with the highest 5-year
graft survival rates were valvular heart disease (80%)
and cardiomyopathy (72%). Retransplantation had the
lowest 1- and 5-year graft survival rates at 72% and 50%,
respectively.
While not enough time has passed to permit 3- and 5-year
analysis of graft survival differences based on current
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Figure 5: Patient survival among heart transplant recipients.
Source: 2002 OPTN/SRTR Annual Report, Table 11.9. Cohorts
are for transplants performed during, 1999–2000 for 3-month and
1-year; 1997–1998 for 3-year; and 1995–1996 for 5-year survival.
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waiting list status designations, 1-year survival was high-
est for Status 2 (88%), intermediate for Status 1B (86%),
and lowest for Status 1A (81%). While the total number of
heterotopic heart transplants was small, decreased graft
survival was observed at all time points for this procedure
compared with orthotopic transplantation. Three-year graft
survival for heterotopic heart transplants was 58% vs.
75% for orthotopic procedures; 5-year survival was 44%
vs. 60%, respectively. A donor age greater than 50 years
was associated with a lower 5-year graft and patient sur-
vival than younger donor age groups.
Data from the Registry of the International Society for
Heart and Lung Transplantation (9,10) provides inform-
ation on over 55 000 cardiac transplants worldwide. Actuar-
ial survival over the past two decades shows a patient
half-life of 9 years with a conditional half-life of 12 years.
Risk factors for 1-year mortality in adult cardiac transplant-
ation include preoperative ventilator dependence, prior
cardiac transplantation, congenital heart disease as the
indication, preoperative ventricular assist or intra-aortic
balloon pump dependence, use of a female donor in a
male recipient, increasing recipient age beyond 50 years
and increasing donor age beyond 20 years, and increasing
donor ischemic time. Risk factors for 5-year mortality in
adult cardiac transplantation include preoperative ventila-
tor dependence, prior cardiac transplantation, congenital
heart disease or coronary artery disease as the indication,
use of a female donor in a male recipient, increasing
recipient age beyond 50 years and increasing donor age
beyond 20 years, and increasing donor ischemic time. Risk
factors for 1-year mortality in pediatric cardiac transplant-
ation include preoperative ventilator dependence, prior
cardiac transplantation, congenital heart disease as the
indication, preoperative ventricular assist or intra-aortic
balloon pump dependence, transplant era, and decreasing
recipient age below 6 years and increasing donor age
beyond 20 years. Risk factors for 5-year mortality in pedi-
atric cardiac transplantation include preoperative ventilator
dependence, prior cardiac transplantation, being a female
recipient, and decreasing recipient age below 6 years and
increasing donor age beyond 20 years. At 1-year follow-up,
the majority of deaths are because of infection and acute
rejection. By 5 years, the majority of deaths are secondary
to chronic rejection, malignancy, and nonspecific forms of
graft failure.
Lung
Lung waiting list characteristics
The lung waiting list continued to expand during the past
year, reaching a record high of 3802 registrants as of
December 31, 2001. This growth reflects a 5% increase
in the number of registrants on the waiting list at the end
of 2000 and a 301% increase since 1992. However, over
the past 3 years, the number of active registrants on the
year-end waiting list stabilized at approximately 2500
registrants, and the number of new registrations stabilized
near approximately 2000 patients per year.
A trend toward increased numbers of patients with inac-
tive status on a waiting list snapshot, as seen in Figure 6,
partially accounts for the observed increase in the total
number of registrants on the lung waiting list, with a 21%
increase among patients placed in an inactive status since
the year 2000 and a more than threefold increase since
1995. Although a patient’s status may change to inactive
as temporary health concerns prohibiting successful trans-
plantation resolve themselves, it is likely that other
patients are listed early in order to accrue time. These
patients may then be temporarily inactivated if not ill
enough to be transplanted when they rise high enough
on the waiting list to actually receive a transplant.
Currently, longer waiting list time is the most influential
determinant of higher organ prioritization, aside from
geographical proximity and blood compatibility. Remaining
inactive on the waiting list, rather than being removed from
the list, allows for accrued time to be maintained in the event
transplantation once again becomes the desired option.
Compared with 10 years ago, in 2001 a higher percentage
of lung waiting list registrants at year-end were older than
age 50, with an increase from 36% in 1992 to 48% in
2001 (Figure 7). Also, in 2001 a higher percentage of regis-
trants on the lung waiting list were African American (5%
in 1992 and 10% in 2001). Increases in Hispanic/Latino
registrants from 1% to 5% were also observed. The most
common characteristics of registrants on the waiting list
as of December 31, 2001, were being female (58%), older
than 50 years of age (48%), white (88%), blood type O
(49%), a US resident (98%), and a patient awaiting a first
transplant (97%). Approximately 61% of the registrants on
the waiting list at the end of 2001 had been waiting more
than a year for an available organ, with 61% of these regis-
trants having waiting list times longer than 2 years (these
waiting times include periods of inactive waiting list status).
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Figure 6: Active vs. inactive lung waiting list patients at year-end,
1995–2001. Source: 2002 OPTN/SRTR Annual Report, Table 12.1.
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Although observed quantiles of time to transplant showed
a tendency to increase between 1992 and 1999, data
available as of December 31, 2001 suggest a partial rever-
sal of this trend, perhaps related to the stabilization of new
lung waiting list registrations seen since 1997. As shown
in Figure 8, 25% of recipients in 1999 were transplanted
within 476 days of listing, whereas in 2001 this same
percentage of recipients was transplanted within
290 days of listing. This represents a 39% reduction in
this quartile of time to transplant. However, this same
25th percentile of time to transplant in 2001 was still
22% higher than seen in 1992. Counterbalancing trends
toward longer times to transplant through 1999 were
decreasing annual death rates on the waiting list (Figure 9).
These decreased from 280 deaths per 1000 patient years
at risk in 1992 to a 10-year low of 134 in 2001. These
decreases result, in part, from improving concomitant care
for end-stage lung patients over time but are also influ-
enced by the wider range of prognoses for currently listed
patients as opposed to 1992.
For patients listed in 2000, more favorable times to trans-
plant were observed in candidates greater than 50 years
old, with 25% of recipients aged 50–64 years transplanted
within 290 days and 25% of recipients over age 65 being
transplanted within 67 days in 2000. In contrast, 25% of
patients aged 11–17 years, 18–34 years, and 35–49 years
were being transplanted within 575 days, 601 days, and
509 days, respectively. Greater organ acceptance may be
contributing to the shorter times to transplant in older
waiting list patients. Ten-year lows of 123, 108, and 131
annual deaths per 1000 patient years on the lung waiting
list were observed in 2001 for patients aged 11–17 years,
35–49 years, and 50–64 years. As of 2001, lung waiting list
patients aged 1–5 years were observed to have the high-
est annual death rate by age group (362 deaths per 1000
patient years).
During the past 10 years, a comparable number of men
and women underwent lung transplantation. Because at
least 10% and as many as 20% more women than men
were on the waiting list over the past decade, the
observed quantiles for time to transplant in women
showed a tendency to be larger than those for men during
the reported period. Annual death rates per 1000 patient
years at risk on the waiting list were usually slightly higher
for men than for women during this same period, with 146
vs. 125 annual deaths per 1000 patient years, respectively,
seen in 2001.
During the past few years, white patients experienced
lower death rates and times to transplant than patients
of other races on the lung waiting list. In 2001, the annual
death rates per 1000 patient years were 130, 147, and 214
for white, African American, and Asian patients, respect-
ively. In terms of times to transplant, 10% of white,
African American, and Asian patients added to the waiting
list in 2001 were transplanted within 83 days, 104 days,
and 301 days, respectively. It should be noted that only 19
Asian patients were added to the waiting list during 2001.
Lung transplantation is now more widely accepted as a
viable treatment alternative for end-stage lung disease
than was the case 10 years ago, with an associated
expansion in the profile of potential transplant candi-
dates. Although recent international guidelines have been
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Figure 7: Age distribution of lung waiting list at year-end,
1992–2001. Source: 2002 OPTN/SRTR Annual Report, Table 12.1.
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Figure 8: 25th percentile time to transplant of new lung waiting
list registrants, 1992–2001. Source: 2002 OPTN/SRTR Annual
Report, Table 12.2.
0
50
100
150
200
250
300
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
An
nu
al
 D
ea
th
 R
at
e
(pe
r 1
00
0 p
ati
en
t y
ea
rs 
at 
ris
k)
Year
Figure 9: Annual death rates per thousand patient years at risk on
the lung waiting list, 1992–2001. Source: 2002 OPTN/SRTR
Annual Report, Table 12.3.
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developed for determining candidates for lung transplant-
ation, the timing of such decisions are still highly influenced
by individual patient considerations. The increased pres-
sure to place patients on the waiting list at earlier stages
of lung disease in response to longer average times to
organ availability has been commented on recently in the
context of cystic fibrosis, pulmonary fibrosis, and
sarcoidosis (11–15). These trends toward earlier diag-
nosed and more broadly defined waiting list patients are
not without consequences. In describing 5-year survival
rates for wait-listed cystic fibrosis patients, Liou et al. (16)
recently argued that an increase in the number of patients
with long survival rates on the waiting list has a deleteri-
ous effect on survival for patients with poorer prognosis
competing for the same organs. Increasing numbers of
patients with better prognoses joining the waiting list may
also result in further increases in the average time to
transplant, exacerbating problems associated with the
organ shortage. Potential approaches for increasing the
average years of life saved per organ via risk-based wait-
ing list prioritizations are growing in popularity (16–21).
These may eventually reduce the inclination toward
placing candidates on the waiting list at earlier stages of
disease. The OPTN/UNOS Thoracic Committee is cur-
rently investigating allocation algorithms for this purpose,
with the objective of creating priority on the waiting list
determined by risk of death on the waiting list and post-
transplant survival (22).
Lung transplant recipient characteristics
A review of data on the characteristics of lung transplant
recipients suggests interesting trends. An examination of
demographic data suggests a rise in the proportion of
recipients older than 50 years of age. This trend is most
evident in the years since 1998. In addition, the vast
majority of recipients were characterized as white
(> 90% for each of the 10 years reported). The gender
distribution over the years varied slightly with an
approximately equal distribution between male and female
recipients.
The majority of recipients did not undergo previous lung or
heart transplantation. Furthermore, the majority of recipi-
ents were not hospitalized at the time of transplantation,
and only a minority of patients were on life support when
transplanted. Importantly, in comparison with 1992–1994,
when more than 60% of lung transplant procedures
involved single lung transplants, the years 1995–2001
suggest an increasing use of double lung transplantation
(Figure 10). The rationale behind this change is not
obvious, as the percentage of transplants for emphy-
sema/chronic obstructive pulmonary disease or alpha-1-
antitrypsin deficiency increased over the same period of
time, a diagnosis for which single lung transplantation has
been felt to be an appropriate procedure (23). Similarly,
the percentage of transplants for cystic fibrosis (CF), a
widely accepted indication for double lung transplantation
(24), remained stable over this time period. These data
may suggest an increasing acceptance of double lung
transplantation as a preferential procedure for many
patients, including those with emphysema (25). The
impact of this practice on the availability of double lungs
for cystic fibrosis and pulmonary hypertensive patients
needs to be monitored.
Death rates in the overall recipient population decreased
over the 10 years reported (Figure 11). This decrease was
most evident for the years after 1992–1993. A similar
decrease in annual death rates is noted when patients
are divided into racial and ethnic categories. It is also
evident that the highest death rates are consistently
noted for patients over 65 years of age at transplantation.
This finding is consistent with other published data (26).
Furthermore, it is apparent that African American recipi-
ents experienced a higher annual death rate than whites,
except in the most recent year (Figure 11). Although a
marked discrepancy was noted in annual death rates by
gender in the early 1990s, with rates for men exceeding
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Figure 10: Percent of patients undergoing single-lung
transplantation, double-lung transplantation and the indication for
transplantation, 1992–2001. Source: 2002 OPTN/SRTR Annual
Report, Table 12.4.
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Figure 11: Annual death rates for lung transplant recipients by
race and total, 1992–2001. Source: 2002 OPTN/SRTR Annual
Report, Table 12.7.
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those for women, this is less evident in more recent years
(Figure 12). Similarly, no consistent difference in death
rates was noted when patients were segregated by
blood type of recipient.
Consistently higher death rates were noted among
patients transplanted while hospitalized in the ICU and
among those on life support at time of transplantation. A
consistently higher annual death rate is noted for patients
with idiopathic pulmonary fibrosis (IPF) in contrast to
patients with emphysema/chronic obstructive pulmonary
disease, cystic fibrosis, alpha-1-antitrypsin deficiency, or
those with primary pulmonary hypertension (PPH)
(Figure 13). This supports the findings of other retro-
spective series (20,27).
Data on graft survival and patient survival tend to correl-
ate. Graft failure within the first 3 months after transplant-
ation was similar among most recipient demographic
groups. As expected, greater early graft failure occurred
among patients hospitalized or requiring life support at the
time of transplantation. Similar findings are noted for early
patient survival. Graft failure and patient survival appear
most compromised in recipients with IPF, PPH, and
congenital disease. An interesting observation is evident
concerning graft survival (Figure 14) and patient survival
(Figure 15) as a function of transplant center volume.
Although early outcomes seem similar, graft survival and
patient survival seem lower in centers with the lowest
transplant volume. This would be consistent with similar
recent findings for other surgical procedures (28).
Heart–Lung
Heart–lung waiting list characteristics
After rising steadily between 1992 and 1998, the total
number of registrants awaiting heart–lung transplant
decreased by 18% over the past 3 years, to 209 as of
the end of 2001. Between 100 and 160 new registrants
were listed for heart–lung transplantation in the United
States each year, with a trend toward a modest decline
toward the lower end of this range over the reporting
interval. The reason for the apparent decline in new regis-
trations may be accounted for partly by prevalent use of
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Figure 12: Annual death rates for lung transplant recipients by
gender and total, 1992–2001. Source: 2002 OPTN/SRTR Annual
Report, Table 12.7.
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Figure 13: Annual death rates for lung transplant recipients by
diagnosis, 1992–2001. Source: 2002 OPTN/SRTR Annual Report,
Table 12.7.
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Figure 14: Graft survival among lung transplant recipients as a
function of transplant volume. Source: 2002 OPTN/SRTR Annual
Report, Table 12.8. Cohorts are for transplants performed during
1999–2000 for 3-month and 1-year; 1997–1998 for 3-year; and
1995–1996 for 5-year survival.
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Figure 15: Patient survival among lung transplant recipients as a
function of transplant volume. Source: 2002 OPTN/SRTR Annual
Report, Table 12.9. Cohorts are for transplants performed during
1999–2000 for 3-month and 1-year; 1997–1998 for 3-year; and
1995–1996 for 5-year survival.
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prostanoid-based pulmonary vasodilator strategies for
PPH, coupled with increasing acceptance of lung trans-
plantation (without the heart). No other emerging patient
management strategies for other diagnoses associated
with heart–lung transplant (e.g. Eisenmenger’s syndrome)
offer an obvious explanation for the decline in new regis-
trations, although earlier recognition and correction of con-
genital heart lesions leading to Eisenmenger’s may be
responsible.
The age of registrants listed for heart–lung transplant over
the past decade increased gradually, with patients aged
35–49 years now predominating over those aged 18–34
years. The proportion of minority registrants increased
over the past decade. The percentage of African American
registrants listed increased from 4% to 13%, while the
Hispanic/Latino population increased since 1994.
The number of reported deaths while waiting on the
heart–lung list remained constant at about 40 per year
(range 28–57). The waiting list death rate is among the
highest for any group of transplant patients, reflecting the
scarcity of donor organs and the absence of other thera-
peutic options for patients with end stage heart-and-lung
failure. Despite the declining number of new registrations,
the year-end census of candidates waiting for heart–lung
transplant remained relatively stable over the past decade.
After rising steadily from 180 to 254 registrants listed
between 1992 and 1998, the number decreased by
approximately 25 patients per year for 2 consecutive
years, to 209 as of 2001. Although the decline in the
total number of candidates listed for heart–lung transplant
coincided with the change in the heart allocation policy
enacted in 1999, neither the number of heart–lung trans-
plants performed nor the reported deaths while waiting
increased. Thus, the decline in new registrations, coupled
with an apparent increase in patients removed from the
waiting list for whom outcome was unknown, account for
most of the recent decline in the year-end census of
patients awaiting heart–lung transplant.
The 25th percentile for time to transplant appears to have
declined, from a high of over 700 days for patients listed in
1997 to just under 400 days for patients listed in 1999. If
borne out by future data, this trend suggests that policy
changes regarding donor heart allocation quite possibly
have had the intended effect of directing more organs to
candidates on the heart–lung waiting list. It remains true,
however, that only a minority of listed registrants actually
receive a heart–lung transplant and that most recipients
wait more than 2 years. Further changes in the allocation
of heart/lung are being considered by the OPTN/UNOS
Thoracic Committee.
Heart–lung transplant recipient characteristics
En bloc heart–lung transplantation is a rarely performed
procedure, and it continues to decrease in frequency,
with only 27 cases reported in 2001. The reasons why
this procedure is disappearing include continued improve-
ment in the outcomes of double lung transplantation for
cystic fibrosis, PPH, and congenital heart disease and
changes in allocation policy, which disenfranchise heart–
lung recipients. Since, in most regions of the United
States Status 1A heart patients receive priority over poten-
tial heart–lung recipients, potential heart–lung recipients
often do not receive organs until they develop end-stage
right heart failure and are listed as Status 1A, often using
subcategory ‘e’ criteria. Over the last decade, the majority
of patients were aged 35–49 years. Throughout the
decade, approximately 40% of heart–lung transplants for
which indications were reported were performed for con-
genital heart disease (primarily Eisenmenger’s syndrome),
and PPH with irreversible heart failure accounted for
approximately 20%. Not surprisingly, the number of recipi-
ents hospitalized preoperatively rose, perhaps reflecting
the consequences of allocation policy.
The annual death rate for patients undergoing heart–lung
transplantation remains high compared with other organs,
but it has dropped consistently since 1997. Actuarial graft
(or patient) survival at the early time points lagged behind
that for double lung transplantation, but at 5 years, survival
was equivalent at approximately 45%. This early differ-
ence undoubtedly is related to both the increased acuity
of patients undergoing a heart–lung transplant and the
increased percentage of patients receiving this procedure
for congenital heart disease or PPH. Subgroup analysis is
limited by sample size, but, clearly, recipients who were in
the ICU at the time of transplant had a substantially higher
perioperative (3 month) mortality, 39% vs. 16%.
In summary, heart–lung transplantation is a procedure
having a long-term outcome equivalent to that for double
lung transplantation. Organ allocation policy and a narrow-
ing of indications are the factors that will likely continue to
make this procedure one that is seldom performed.
Impact of Policy and Thoracic
Transplantation
Effect of OPTN policy changes on the heart waiting list
and heart transplantation
On January 20, 1999, a major revision to the OPTN heart
allocation policy expanded the existing categories of Sta-
tus 1 and Status 2 to Status 1A, 1B, and 2. Three other
policy changes, perhaps less far-reaching but still crucial in
terms of effect on patient groups, also occurred during the
last 10 years. On May 3, 1993, the heart allocation policy
was modified to allow the listing and prioritization of
in utero candidates. On January 3, 1995, policy changed so
that only time waiting in Status 1 was used for prioritiza-
tion of patients, instead of total active waiting time. And,
as of September 6, 2000, candidates added to the waiting
list prior to their 18th birthday would continue to be
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allocated organs as pediatric patients during their entire
waiting period.
Without question, among all these changes, the introduc-
tion of Status 1A and 1B had the greatest effect on heart
candidates and recipients. Prior to the policy change, Sta-
tus 1 included patients who:
 required cardiac or pulmonary assistance with a total
artificial heart, ventricular assist system, intra-aortic
balloon pump, or ventilator;
 were in the ICU requiring inotropes; or
 were less than 6 months old.
Status 2 included all other actively waiting patients. With a
few exceptions, patients who would have been con-
sidered Status 1 under the prior allocation system would
qualify for either Status 1A or Status 1B under the new
system. The advent of three active statuses allowed for
further delineation and stratification of medical conditions
than previously possible under the two-tiered system.
Furthermore, the new system more accurately reflects
the current care practice for heart failure patients.
The decline in death rates for patients on the heart waiting
list has been substantial. Death rates decreased by almost
half between 1992 and 2001, from 317 to 151 deaths per
1000 patient years. The death rate in 2001 was much
lower than in 1999, both overall and by medical urgency
status. It is possible that some of these trends are the
result of policy change. By transplanting Status 1A
patients before Status 1B patients (who could presumably
endure a long wait), most Status 1A patients could be
transplanted with available organs. Fewer patients there-
fore would die on the waiting list. The substratification of
Status 1 does not explain the decrease in death rates
among Status 2 candidates. This latter finding may reflect
improvements in general medical care for patients with
heart disease while they are on the waiting list.
Overall, the median time to transplant and median waiting
time to transplant for heart patients, unlike those for many
other organs, appear to have decreased during the past
10 years, with a consistent decline since initiation of the
current policy. Though the median time to transplant for
patients added to the waiting list in 1999 in Status 1A was
144 days—about 1 month longer than the wait for Status 1
patients added in 1998—the median time to transplant in
2000 and 2001 was approximately 100 days. For patients
added in Status 1B, the median time to transplant in 2000
and 2001 was similar to that of Status 1A patients; it was
considerably shorter in 1999. Although Status 1A patients
are given priority in the allocation system, this advantage
appears to be balanced out by their higher waiting list
mortality rate, resulting in waiting times for Status 1A
patients almost on a par with those for Status 1B. The
median time to transplant for patients added in Status 2
has always been substantially higher than that for Status 1
patients, but in the current policy era it is even more
disparate. The increase is most obvious for patients
added in Status 2 during 1998 (501 days in 1997 and
649 days in 1998). Because of the long wait experienced
by these patients, most of their time on the waiting list
was actually spent during the current policy era. The
increasing disparity in median time to transplant for Sta-
tus 2 compared with Status 1A and 1B may result from the
current policy. As more Status1A and Status 1B patients are
transplanted, fewer organs are available for Status2 patients.
Candidates added to the list before their 18th birthday are
considered pediatric patients for allocation purposes
throughout their entire waiting period. Thus, candidates
who had begun accruing status-specific waiting time
based on pediatric definitions of status would continue
to do so regardless of their current age. The percentage
of candidates who were younger than 18 years when
listed, but 18 or older at year-end and still on the waiting
list, grew from three patients in 1992 to 37 in 2001 (3%
and 13%, respectively). Though the percentage between
1999 and 2000 dropped slightly (from 12% to 11%,
respectively), there was a subsequent resurgence in
2001. As a relatively small number of patients are affected
by this policy and because its implementation is recent, an
accurate assessment of its impact is not yet possible.
The percentage of patients who were more urgent (i.e.
Status 1, Status 1A, or Status 1B) at transplant increased
fairly rapidly between 1992 and 1998, from 40% to 74%.
However, this percentage has stayed relatively constant
since then, ranging only from 70% to 75%. It appears
therefore that the policy change had little impact overall
on the distribution of Status 1 patients (including 1A and
1B) compared with those who are Status 2. It remains to
be seen whether the relative balance between the percent-
age of patients transplanted in Status 1A compared with
Status 1B will continue.
Because of the conventions used to calculate patient sur-
vival, it is better to assess the impact of the policy on post-
transplant outcomes by looking at graft survival. One-year
graft survival rates rose slowly and fairly consistently for
transplants performed between 1991 and 1998, from 81%
to 85%. By 2000, the status-specific 1-year survival rates
also recovered and actually surpassed those in 1998. One
possible explanation is the change in prioritization of can-
didates in January 1999. This change may have had an
impact on graft survival initially, given the preponderance
of more urgently ill patients who had been waiting for a
considerable time. Those who received a transplant were
the sickest of the sick. The second year after the policy
change, Status 1A patients were perhaps being trans-
planted at a more optimal time, yielding better outcomes.
Further follow-up will need to accrue before a definitive
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conclusion can be made about the impact of the policy
change on survival.
Effect of policy change on the lung waiting list and lung
transplantation
The lung allocation policy experienced only minor modifi-
cations during the past 10 years. Within the group of can-
didates who are blood group compatible with the donor
and are within the size range specified by the transplant
program, the ordering of potential recipients is primarily
based on time actively waiting. The most substantial
change to the algorithm during the last decade was the
adjustment to waiting time for lung transplant candidates
diagnosed with IPF. As of July 3, 1995, candidates
received 90 days of waiting time in addition to their waiting
time since listing. The policy modification was imple-
mented as an attempt to transplant IPF patients earlier,
thereby reducing the high waiting list mortality compared
with other diagnostic categories. The death rates per
patient year spent on the waiting list declined dramatically
for IPF patients between 1995 and 1996, as did those for
other diagnoses. In spite of the decline, a substantial gap
still exists between death rates for IPF patients and all
other diagnoses, with many diagnoses having a death rate
less than half that for IPF. There appears no major alteration
in the percentage of IPF patients who received a transplant.
Though diagnosis at transplant fluctuated somewhat over
the period, it does appear that IPF patients have been
receiving a slightly higher proportion of transplants since
the policy modification. Between 1992 and 1994, 11–12%
of the recipients were diagnosed with IPF; in 1996, the
first complete calendar year following the policy change,
17% of recipients had IPF. Since then, the percentage has
ranged from 14% to 17%. With the exception of emphy-
sema/chronic obstructive pulmonary disease and cystic
fibrosis, the percentage of transplants in all of the other
major diagnostic categories has decreased during the era
of this report. One-year patient survival for lung transplant
recipients has been relatively stable at 71–78% between
1993 and 2000, with the notable exception of 1996, when
the 1-year survival rate was 71%.
Conclusions
Important trends over the past decade are documented for
heart, lung, and heart–lung waiting lists and for corresponding
organ transplant recipients. Wait-listed candidates and thor-
acic organ recipients include increasing percentages of older
age groups. Post-transplant patient survival rates and graft
survival rates have gradually improved over the last decade.
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